Skip to content

Arginine Synthesis in Healthy Adult Humans

Arginine Synthesis in Healthy Adult Humans: Does Proline or Glutamate Provide the 5-Carbon Chain?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01912235
Enrollment
6
Registered
2013-07-31
Start date
2007-09-30
Completion date
2008-06-30
Last updated
2018-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Arginine synthesis, 15N2 arginine, 1-13C Glutamine, 2-15N Glutamine, 15N Proline

Brief summary

Arginine synthesis in mammals is a complex process involving at least 8 enzymes and intracellular and interorgan transfer of substrates. The investigators have shown in our neonatal studies that there is no conversion of glutamate to arginine but proline label appears in ornithine, citrulline and arginine. It is clear therefore that arginine is synthesized in human neonates from proline. In adults the source of the carbon backbone is less clear.

Detailed description

Through a series of test in healthy adults using tandem mass spectrometry with carbon labeled GLN and nitrogen labeled PRO to determine the dietary source for the carbon chain of ORN, CIT and ARG. Additionally, using Nitrogen labeled GLN, we will identify the source of the nitrogen atoms in these amino acids. Using guanidino - 15N2 arginine, 1-13C Glutamine, 2-15N Glutamine and 15N Proline we will be able to: 1. determine the flux of arginine and proline in healthy adult volunteers 2. determine and compare the flux of carbon and nitrogen labeled glutamine 3. demonstrate whether glutamine or proline provides the carbon backbone for ornithine, citrulline and arginine in adults. 4. the source of the N atoms in ornithine, citrulline and arginine.

Interventions

OTHER2-15N glutamine

Glutamine with N15 isotope tracer

OTHER15N2 arginine and 15N proline

Arginine and Proline isotope tracers

OTHER1-13C glutamine

Glutamine carbon isotope tracer

Sponsors

The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* 5 men of average weight 80 kg will be studied * healthy, with no know disease of liver, and/or kidney * weight stable

Exclusion criteria

* weith loss or gain over the last three months * on medications known to affect amino acid metabolism * known liver, kidney disease condition

Design outcomes

Primary

MeasureTime frame
Blood Isotope Levels8 hours

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026